留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

实体器官移植后淋巴组织增生性疾病的研究进展

明英姿,  彭博,  成柯,  赵于军,  佘兴国,  牛英,  庄权,  张朋朋,  刘洪

downloadPDF
文章导航 > 器官移植  > 2017 >  8(2): 89-98
明英姿, 彭博, 成柯, 等. 实体器官移植后淋巴组织增生性疾病的研究进展[J]. 器官移植, 2017, 8(2): 89-98. doi: 10.3969/j.issn.1674-7445.2017.02.002
引用本文: 明英姿, 彭博, 成柯, 等. 实体器官移植后淋巴组织增生性疾病的研究进展[J]. 器官移植, 2017, 8(2): 89-98. doi: 10.3969/j.issn.1674-7445.2017.02.002
shu

实体器官移植后淋巴组织增生性疾病的研究进展

doi: 10.3969/j.issn.1674-7445.2017.02.002

  • 410013 长沙，中南大学湘雅三院移植中心 国家卫生和计划生育委员会器官移植工程技术研究中心

基金项目: 

吴阶平医学基金会临床科研专项资助基金 320.6750.15070

详细信息
    作者简介:

    明英姿，医学博士，主任医师，硕士研究生导师。现任中南大学湘雅三医院移植中心主任，主持移植中心工作。本科毕业于同济医科大学临床医学专业德语医学班，硕士、博士均毕业于同济医院器官移植研究所，曾留学德国两年余。兼任中国移植透析研究委员会常务委员、中国研究型医院学会移植医学专业委员会常务委员、中国医师协会器官移植分会青年委员会副主任委员、中华器官移植专业委员会肝移植学组委员、湖南省器官移植专业委员会候任主任委员、湖南省器官移植质量控制中心委员、湖南省人体器官移植技术临床应用委员会专家，湖南省卫生厅及湖南省红十字会人体器官捐献专家组专家。兼任《器官移植》、《Hepatobiliary & Pancreatic Diseases International》、《Journal of Organ Donation and Transplantation》、《中华移植杂志（电子版）》等国内外多家杂志编委。多年来一直从事器官移植的临床、教学及科研工作，作为第一手术者能够熟练开展腹部大器官移植，包括肝移植（包括经典式肝移植和背驮式肝移植）、肾移植（首次肾移植、多次肾移植、亲属活体肾移植）及肝肾联合移植，其中二次以上肾移植已完成近百例。先后获得“湘雅名医”、“湖南省高校青年骨干教师”等称号

    通讯作者:

    刘洪, Email: 923088107@qq.com

  • 中图分类号: R617, R733.4

    摘要
  • 摘要: 移植后淋巴组织增生性疾病（PTLD）是一种在实体器官移植后最常见的、严重危及生命的肿瘤性并发症。PTLD包含了一系列疾病，根据世界卫生组织（WHO）的分型，可以分为早期病变、多形性PTLD、单一型PTLD和经典的霍奇金淋巴瘤4种类型，总发生率可高达20%，与EB病毒感染、免疫抑制程度、遗传因素等相关。PTLD临床表现多样，确诊依赖于病理诊断。一旦确诊PTLD，首要目标为治愈PTLD，其次为保存移植物功能。降低免疫抑制水平通常作为初始治疗，在此基础上进一步联合利妥昔单抗、化学药物治疗、放射治疗等治疗方式进行治疗，其总体有效率和患者总存活时间较以往已有较大提高。由于国内对PTLD的报道较少，未引起足够的重视，因此需进一步增强移植医师对PTLD的认识，提高PTLD的治疗效果。

     

    • HTML全文
    • 参考文献(60)
  • [1] Singavi AK, Harrington AM, Fenske TS. Post-transplant lymphoproliferative disorders[J]. Cancer Treat Res, 2015, 165: 305-327. DOI: 10.1007/978-3-319-13150-4_13.
    [2] Akar Ozkan E, Ozdemir BH, Deniz EE, et al. Posttransplant lymphoproliferative disorder after liver and kidney transplant[J]. Exp Clin Transplant, 2014, 12(Suppl 1): 142-148.
    [3] Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines[J]. Br J Haematol, 2010, 149(5): 675-692. DOI: 10.1111/j.1365-2141.2010.08161.x.
    [4] Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival[J]. Am J Transplant, 2006, 6(5 Pt 1): 1017-1024.
    [5] Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry[J]. Am J Transplant, 2006, 6(11): 2735-2742. doi: 10.1111/ajt.2006.6.issue-11
    [6] Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation[J]. Crit Rev Oncol Hematol, 2005, 56(1): 155-167. doi: 10.1016/j.critrevonc.2005.03.015
    [7] Faull RJ, Hollett P, Mcdonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand[J]. Transplantation, 2005, 80(2): 193-197. doi: 10.1097/01.TP.0000165098.49658.F3
    [8] Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study[J]. Pediatr Transplant, 2002, 6(5): 396-399. doi: 10.1034/j.1399-3046.2002.00021.x
    [9] Boubenider S, Hiesse C, Goupy C, et al. Incidence and consequences of post-transplantation lymphoproliferative disorders[J]. J Nephrol, 1997, 10(3): 136-145.
    [10] Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients[J]. JAMA, 2011, 306(17): 1891-1901. DOI: 10.1001/jama.2011.1592.
    [11] Lee KF, Tsai YT, Lin CY, et al. Cancer incidence among heart, kidney, and liver transplant recipients in Taiwan[J]. PLoS One, 2016, 11(5): e0155602. DOI: 10.1371/journal.pone.0155602.
    [12] Evens AM, Roy R, Sterrenberg D, et al. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy[J]. Curr Oncol Rep, 2010, 12(6): 383-394. DOI: 10.1007/s11912-010-0132-1.
    [13] Knight JS, Tsodikov A, Cibrik DM, et al. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center[J]. J Clin Oncol, 2009, 27(20): 3354-3362. DOI: 10.1200/JCO.2008.20.0857.
    [14] Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?[J]. Am J Surg Pathol, 2000, 24(3): 375-385. doi: 10.1097/00000478-200003000-00006
    [15] Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting[J]. Transplantation, 1999, 68(10): 1517-1525. doi: 10.1097/00007890-199911270-00015
    [16] Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression[J]. Transplantation, 1999, 68(7): 997-1003. doi: 10.1097/00007890-199910150-00017
    [17] Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations[J]. J Heart Lung Transplant, 1995, 14(2): 214-221.
    [18] Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)[J]. Transplantation, 2001, 71(8): 1065-1068. doi: 10.1097/00007890-200104270-00010
    [19] Mcdonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids[J]. Am J Transplant, 2008, 8(5): 984-989. DOI: 10.1111/j.1600-6143.2008.02167.x.
    [20] Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant[J]. Transplantation, 2000, 69(5): 827-833. https://www.researchgate.net/publication/232103602_Epstein-Barr_Virus-Negative_Lymphoproliferative_Disorders_in_Long-Term_Survivors_After_Heart_Kidney_and_Liver_Transplant1
    [21] Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients[J]. Lancet, 1993, 342(8886/8887): 1514-1516. https://www.researchgate.net/publication/15296132_Incidence_of_non-Hodgkin_lymphoma_in_kidney_and_heart_transplant_recipients
    [22] Jagadeesh D, Woda BA, Draper J, et al. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations[J]. Curr Treat Options Oncol, 2012, 13(1): 122-136. DOI: 10.1007/s11864-011-0177-x.
    [23] Opelz G, Naujokat C, Daniel V, et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients[J]. Transplantation, 2006, 81(9): 1227-1233. doi: 10.1097/01.tp.0000219817.18049.36
    [24] Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression[J]. Transplantation, 2005, 80(9): 1233-1243. doi: 10.1097/01.tp.0000179639.98338.39
    [25] Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report[J]. Am J Transplant, 2004, 4(2): 222-230. doi: 10.1046/j.1600-6143.2003.00325.x
    [26] Younes BS, Mcdiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients[J]. Transplantation, 2000, 70(1): 94-99. https://www.researchgate.net/publication/12399545_The_effect_of_immunosuppression_on_posttransplant_lymphoproliferative_disease_in_pediatric_transplant_patients
    [27] Reshef R, Luskin MR, Kamoun M, et al. Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients[J]. Am J Transplant, 2011, 11(4): 817-825. DOI: 10.1111/j.1600-6143.2011.03454.x.
    [28] Pourfarziani V, Einollahi B, Taheri S, et al. Associations of human leukocyte antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation[J]. Ann Transplant, 2007, 12(4): 16-22. https://www.researchgate.net/publication/5507253_Associations_of_Human_Leukocyte_Antigen_HLA_haplotypes_with_risk_of_developing_lymphoproliferative_disorders_after_renal_transplantation
    [29] Subklewe M, Marquis R, Choquet S, et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation[J]. Transplantation, 2006, 82(8): 1093-1100. doi: 10.1097/01.tp.0000235889.05171.12
    [30] Stern M, Opelz G, Dohler B, et al. Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma[J]. Blood, 2010, 115(19): 3960-3965. DOI: 10.1182/blood-2009-10-250134.
    [31] Babel N, Vergopoulos A, Trappe RU, et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients[J]. Transplantation, 2007, 84(3): 387-391. doi: 10.1097/01.tp.0000269617.60751.c4
    [32] Thomas RV, Mcaulay K, Higgins C, et al. Interferon gamma (IFN-gamma) polymorphism in posttransplantation lymphoproliferative disease[J]. Blood, 2005, 106(4): 1502-1503. doi: 10.1182/blood-2005-03-1279
    [33] Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder[J]. Transpl Infect Dis, 2001, 3(2): 70-78. doi: 10.1034/j.1399-3062.2001.003002070.x
    [34] Kapelushnik J, Ariad S, Benharroch D, et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi's sarcoma[J]. Br J Haematol, 2001, 113(2): 425-428. doi: 10.1046/j.1365-2141.2001.02740.x
    [35] Buda A, Caforio A, Calabrese F, et al. Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection[J]. Transpl Int, 2000, 13 (Suppl 1): S402-S405. https://www.researchgate.net/profile/Andrea_Buda/publication/12216192_Lymphoproliferative_disorders_in_heart_transplant_recipients_Role_of_hepatitis_C_virus_HCV_and_Epstein-Barr_virus_EBV_infection/links/541864930cf25ebee9881b0c.pdf
    [36] Dockrell DH, Strickler JG, Paya CV. Epstein-Barr virus-induced T cell lymphoma in solid organ transplant recipients[J]. Clin Infect Dis, 1998, 26(1): 180-182. doi: 10.1086/cid.1998.26.issue-1
    [37] Kwong YL, Lam CC, Chan TM. Post-transplantation lymphoproliferative disease of natural killer cell lineage: a clinicopathological and molecular analysis[J]. Br J Haematol, 2000, 110(1): 197-202. doi: 10.1046/j.1365-2141.2000.02138.x
    [38] Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement[J]. Transplant Proc, 2005, 37(2): 954-955. doi: 10.1016/j.transproceed.2004.12.130
    [39] Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction[J]. Transplantation, 2001, 72(6): 1012-1019. doi: 10.1097/00007890-200109270-00006
    [40] Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients[J]. Blood, 2001, 97(5): 1165-1171. doi: 10.1182/blood.V97.5.1165
    [41] Green M, Bueno J, Rowe D, et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children[J]. Transplantation, 2000, 70(4): 593-596. doi: 10.1097/00007890-200008270-00010
    [42] Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients[J]. Am J Transplant, 2005, 5(9): 2222-2228. doi: 10.1111/ajt.2005.5.issue-9
    [43] Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy[J]. N Engl J Med, 2006, 354(5): 496-507. doi: 10.1056/NEJMra050276
    [44] Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines[J]. Br J Haematol, 2010, 149(5): 693-705. DOI: 10.1111/j.1365-2141.2010.08160.x.
    [45] Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients[J]. Transplantation, 2001, 71(8): 1076-1088. doi: 10.1097/00007890-200104270-00012
    [46] Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (bigstar)[J]. Am J Transplant, 2011, 11(2): 336-347. DOI: 10.1111/j.1600-6143.2010.03387.x.
    [47] Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era[J]. J Clin Oncol, 2010, 28(6): 1038-1046. DOI: 10.1200/JCO.2009.25.4961.
    [48] Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy[J]. Am J Transplant, 2006, 6(3): 569-576. doi: 10.1111/j.1600-6143.2005.01211.x
    [49] Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study[J]. Blood, 2006, 107(8): 3053-3057. doi: 10.1182/blood-2005-01-0377
    [50] Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)[J]. Am J Transplant, 2005, 5(12): 2901-2906. doi: 10.1111/j.1600-6143.2005.01098.x
    [51] Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center[J]. Transplantation, 2005, 80(12): 1692-1698. doi: 10.1097/01.tp.0000185570.41571.df
    [52] Choquet S, Oertel S, Leblond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution[J]. Ann Hematol, 2007, 86(8): 599-607. doi: 10.1007/s00277-007-0298-2
    [53] González-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase Ⅱ trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease[J]. Haematologica, 2007, 92(11): 1489-1494. doi: 10.3324/haematol.11360
    [54] Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial[J]. Lancet Oncol, 2012, 13(2): 196-206. DOI: 10.1016/S1470-2045(11)70300-X.
    [55] Zimmermann H, Trappe RU. Therapeutic options in post-transplant lymphoproliferative disorders[J]. Ther Adv Hematol, 2011, 2(6): 393-407. DOI: 10.1177/2040620711412417.
    [56] Ralf UT, Petra R, Ruth N, et al. Interim analysis of the largest prospective trial to date in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD): introducing risk-stratified sequential treatment (RSST)[J]. J Clin Oncol, 2012, 30(15_suppl): 8030. http://meetinglibrary.asco.org/content/70087?media=vm&poster=1
    [57] Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies[J]. Blood, 2007, 109(6): 2571-2578. doi: 10.1182/blood-2006-01-024703
    [58] Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial[J]. Blood, 2007, 110(4): 1123-1131. doi: 10.1182/blood-2006-12-063008
    [59] Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab[J]. Am J Transplant, 2007, 7(11): 2619-2625. doi: 10.1111/ajt.2007.7.issue-11
    [60] Davis CL. Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder[J]. Transpl Infect Dis, 2001, 3(2): 108-118. doi: 10.1034/j.1399-3062.2001.003002108.x
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  401
  • HTML全文浏览量:  43
  • PDF下载量:  24
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-12-07
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2017-03-15

目录

    /

    返回文章
    返回

    《器官移植》微信订阅号

    《器官移植》微信服务号

    联系我们
    • 电话: 020-38736410
    • Email: organtranspl@163.com
    • 地址: 广州市天河区天河路600号中山大学附属第三医院（广州）期刊有限责任公司
    • 《器官移植》编辑部  粤ICP备2021030844号
    友情链接

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计